Literature DB >> 15082228

Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions.

Alvaro Hermida-Ameijeiras1, Estefanía Méndez-Alvarez, Sofía Sánchez-Iglesias, Carolina Sanmartín-Suárez, Ramón Soto-Otero.   

Abstract

The autoxidation and monoamine oxidase (MAO)-mediated metabolism of dopamine (3-hydroxytyramine; DA) cause a continuous production of hydroxyl radical (*OH), which is further enhanced by the presence of iron (ferrous iron, Fe(2+) and ferric ion, Fe(3+)). The accumulation of hydrogen peroxide (H2O2) in the presence of Fe(2+) appears to discard the involvement of the Fenton reaction in this process. It has been found that the presence of DA significantly reduces the formation of thiobarbituric acid reagent substances (TBARS), which under physiological conditions takes place in mitochondrial preparations. The presence of DA is also able to reduce TBARS formation in mitochondrial preparations even in the presence of iron (Fe(2+) and Fe(3+)). However, DA boosted the carbonyl content of mitochondrial proteins, which was further increased in the presence of iron (Fe(2+) and Fe(3+)). This latter effect is also accompanied by a significant reduction in thiol content of mitochondrial proteins. It has also been observed how the pre-incubation of mitochondria with pargyline, an acetylenic MAO inhibitor, reduces the production of *OH and increases the formation of TBARS. Although, the MAO-mediated metabolism of DA increases MAO-B activity, the presence of iron inhibits both MAO-A and MAO-B activities. Consequently, DA has been shown to be a double-edged sword, because it displays antioxidant properties in relation to both the Fenton reaction and lipid peroxidation and exhibits pro-oxidant properties by causing both generation *OH and oxidation of mitochondrial proteins. Evidently, these pro-oxidant properties of DA help explain the long-term side effects derived from l-DOPA treatment of Parkinson's disease and its exacerbation by the concomitant use of DA metabolism inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082228     DOI: 10.1016/j.neuint.2003.11.018

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  37 in total

1.  Dopamine contamination of infused tyramine.

Authors:  Courtney Holmes; Jeffrey Moak; Basil Eldadah; Ella Zimmerly; Yehonatan Sharabi; David S Goldstein
Journal:  Clin Chem       Date:  2005-07-21       Impact factor: 8.327

2.  Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.

Authors:  Sofía Sánchez-Iglesias; Pablo Rey; Estefanía Méndez-Alvarez; José Luis Labandeira-García; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2006-12-12       Impact factor: 3.996

Review 3.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

4.  Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase.

Authors:  Javier Iglesias-González; Sofía Sánchez-Iglesias; Estefanía Méndez-Álvarez; Sarah Rose; Atsuko Hikima; Peter Jenner; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2012-07-22       Impact factor: 3.996

5.  Chronic cocaine administration causes extensive white matter damage in brain: diffusion tensor imaging and immunohistochemistry studies.

Authors:  Ponnada A Narayana; Juan J Herrera; Kurt H Bockhorst; Emilio Esparza-Coss; Ying Xia; Joel L Steinberg; F Gerard Moeller
Journal:  Psychiatry Res       Date:  2014-01-23       Impact factor: 3.222

6.  Early abstinence of crack-cocaine is effective to attenuate oxidative stress and to improve antioxidant defences.

Authors:  Aline Zaparte; Thiago W Viola; Rodrigo Grassi-Oliveira; Maurilio da Silva Morrone; José C Moreira; Moisés E Bauer
Journal:  Psychopharmacology (Berl)       Date:  2014-10-23       Impact factor: 4.530

7.  Inhibition of the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxidative stress in Parkinson's disease.

Authors:  Dianlu Jiang; Shuyun Shi; Lin Zhang; Lin Liu; Bingrong Ding; Bingqing Zhao; Gargey Yagnik; Feimeng Zhou
Journal:  ACS Chem Neurosci       Date:  2013-07-17       Impact factor: 4.418

8.  Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system.

Authors:  Jorge Durán-González; Edna D Michi; Brisa Elorza; Miriam G Perez-Córdova; Luis F Pacheco-Otalora; Ahmed Touhami; Pamela Paulson; George Perry; Ian V Murray; Luis V Colom
Journal:  Neurobiol Aging       Date:  2013-03-07       Impact factor: 4.673

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Oxidant/antioxidant status in obese adolescent females with acne vulgaris.

Authors:  Khalid O Abulnaja
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.